Navigation Links
Taxane in Medical News

Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer

...nt demographics and key ovarian cancer disease characteristics, including age, ECOG Performance Status, presence of bulky disease and history of prior taxane therapy. A greater number of patients (13, 20%) had platinum refractory disease on the TELCYTA plus PLD arm compared to (8, 13%) with the PLD arm. ...

Research Findings on Nine GlaxoSmithKline Cancer Compounds to be Presented at ASCO 2009

...tients with advanced or metastatic breast cancer whose tumors overexpress HER2/ErbB2 and who have received prior therapy including an anthracycline, a taxane and trastuzumab. On June 10, 2008, the European Commission granted a conditional marketing authorization for lapatinib in all 27 European Union (E.U.)...

Drug May Help Against Inflammatory Breast Cancer

...kin of more than two-thirds of the breast, tenderness, hardening and warming of the breast. For patients resistant to conventional anthracycline or taxane and trastuzumab, treatment options are limited. Lapatinib inhibits HER2, a protein that's expressed much more in inflammatory breast cancer than in ot...

Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer

...greed to by FDA, will assess the capacity of farletuzumab to extend progression free survival and overall survival in combination with carboplatin and taxane at two different dose levels of farletuzumab. The study will be conducted as a randomized, double-blind, placebo-controlled trial. Morphotek expects ...

Non-Hormonal Therapies Aid Breast Cancer Patients

...n overall death, compared with older single-agent chemotherapy. Single drug taxane treatment led to a relative risk reduction of 33 percent, while a combination of a taxane with capecitabine or gemcitabine led to a 51 percent relative risk reductio...

Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium

...ong North Carolina metastatic breast cancer patients treated with Xeloda or taxane monotherapy. -- Dec. 14, 7:00 to 9:00 a.m., [Poster No. 6107], Cape...urvival outcome is similar for first-line chemotherapy with capecitabine or taxane for metastatic breast cancer (Lead Author: Gretchen Kimmick) The ma...

FDA Accepts Genta's NDA Amendment as Complete Response for Genasense(R) Treatment of Chronic Lymphocytic Leukemia

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...

Also in the May 27 JNCI

...acted follow-up, the authors write. A retrospective analysis of the data failed to detect a subgroup of patients who were more likely to respond to taxane therapy on the basis of their tumors expression of the estrogen receptor and HER2. In an accompanying editorial, Clifford Hudis, M.D., and Chau Dan...

Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane, Tesetaxel

..." About Tesetaxel Tesetaxel is a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. However, bo...ule, tesetaxel was developed to maintain the high antitumor activity of the taxane drug class while eliminating infusion reactions, reducing neuropathy, and i...

New study of targeted therapies for breast cancer -- model for global clinical trials

...he treatment of advanced or metastatic HER2-positive breast cancer in patients who had received prior therapy with three agents -- an anthracycline, a taxane and Herceptin. GlaxoSmithKline is providing the study drug, as well as additional financial support for the ALTTO trial. All drugs carry potential sid...
Taxane in Medical Technology

FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral Taxane

Clinical Studies Expected to Restart in Second Half 2008 BERKELEY HEIGHTS, N.J., June 23 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced that the Company has received notification from the U.S. Food and Drug Administration (FDA) that Genta may resume c...

ADVENTRX Announces Results From ANX-514 Bioequivalence Study

...mary endpoint of the study, was not demonstrated based on benchmark regulatory standards. "Following discussions with clinicians and experts in taxane pharmacokinetics, we believe that the increased blood-levels of docetaxel, which we observed solely during the first hour of a 168-hour observation pe...

BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial

...the U.S. Tavocept Trial involved cisplatin and the taxane drug docetaxel while the Japan Tavocept Trial involved cisplatin and the taxane drug paclitaxel, BioNumerik has also now observed ...reatment regimens utilizing two different types of taxane chemotherapy drugs. "It is also important to con...

Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...

EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting

...10620/ENMDLOGO ) For this Phase 2 single agent, open label study, a total of 65 patients who had previously received at least one anthracycline and taxane therapy were enrolled. 55 patients were evaluable for tumor response. Of the evaluable patients, the antitumor activity observed with MKC-1 included 3...

ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)

...ts who are Herceptin receptor (Her2/neu) negative and who have failed prior taxane and anthracycline therapies. Data available from 31 patients indicated a 23...n in patients with advanced breast cancer who have failed anthracycline and taxane chemotherapies with clearly defined criteria. The primary endpoint for the ...

Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies

...ongly predicted benefit from treatment with docetaxel (Taxotere), a type of taxane commonly used for breast cancer therapy. A genomic classifier predicting di... biology of breast cancer and now, possibly, treatment benefit for a common taxane regimen with our ongoing study of the utility of Oncotype DX and additional...

Genasense(R) Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...

Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...

Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...
Taxane in Biological News

Common chemotherapy drug triggers fatal allergic reactions

...rse Event Report System between 1997 and 2007 with 109 (38 percent) deaths in patients who received Cremophor-based paclitaxel, a solvent-administered taxane chemotherapy. Adverse event reports generally only represent from 1 to 10 percent of actual incidence, so the number of hypersensitivity reactions...

Eribulin mesylate demonstrated anti-tumor activity in patients with advanced breast cancer

...edian of four prior chemotherapy regimens that included an anthracycline, a taxane and capecitabine. About Study 211 Study 211 is a Phase II, open-label, s...y advanced or metastatic breast cancer who had received an anthracycline, a taxane and capecitabine as prior therapy, and who were refractory to their last ch...

Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer

... Berlin, Germany: Women with a particularly aggressive form of breast cancer seem to do better if they are treated with a combined anthracycline and taxane chemotherapy regimen before surgery, together with trastuzumab (Herceptin) before and after surgery, according to results from the largest multi-centr...

Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors

...searchers now plan to investigate the effects of adjuvant and neo-adjuvant treatments in women with BRCA1/2-associated breast cancers, and to evaluate taxane and platinum therapies further. ...
Taxane in Biological Technology

Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane

Company Also Completes FDA Submission for Removal of Clinical Hold BERKELEY HEIGHTS, N.J., June 10 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced that the Company has received notice of allowances for two major patents from the European Patent Office for i...

First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer

...gle arm studies encompassing two treatment regimens (every 14 days or every 21 days). Patients include those with metastatic breast cancer with prior taxane treatment, those with metastatic, platinum-resistant ovarian cancer and those with metastatic cervical cancer. The trials are designed to evaluate th...

Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer

...he potential for additional uses of picoplatin as a combination therapy in the treatment of non-small cell lung and ovarian cancers where platinum and taxane combinations are currently used." About Picoplatin Picoplatin has an improved safety profile relative to existing platinum-based cancer therapies ...

Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same drug class as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the Uni...

Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008

...udy, performed in Serbia and Poland, MVA-BN(R)-HER2 is being evaluated following first or second-line chemotherapy or in combination with single-agent taxane chemotherapy. Both studies evaluate treatment of metastatic breast cancer patients, whose tumors overexpress HER2. Patients are vaccinated 3 times, at...

Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights

...w us to resume clinical trials with a leading oral taxane that addresses a large, well-characterized market....e proposed indication. Tesetaxel: A Leading Oral taxane with Anticancer Activity In other regulatory act...esetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same drug class as paclitaxel and d...

Genta Announces Second Quarter 2008 Financial Results and Conference Call

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same drug class as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the Uni...

Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia

...tial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi- synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...

Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...

Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights

...strategy -- Tesetaxel in-licensed -- leading oral taxane and new clinical-stage product -- FDA provide...s to tesetaxel has provided us with a leading oral taxane that addresses a very large and well-characterized...e efficacy and safety. Tesetaxel: A Leading Oral taxane with Anticancer Activity Tesetaxel is the latest...
Other Tags
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/12/2014)... PALM BEACH GARDENS, Fla. , Nov. 12, 2014 ... management solutions, announced today that its U.are.U ® ... upscale retail bakery chain in Central Mexico ... solution in June 2014 to eliminate payroll issues caused ... Prior to installing the U.are.U fingerprint readers, Montparnasse ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
Other Contents